cisplatin,nivolumab,gemcitabine
bms
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivolumab', 'gemcitabine', 'nivo', 'mibc', 'hcrn,gu,16-257', 'gu ', 'bladder', 'cisplatin']
don't miss, #gu23 rapid abstract presentation from - co-primary endpoint analysis of hcrn gu 16-257: phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with #mibc 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology